Compartilhar
Informação da revista

Estatísticas

Siga este link para acessar o texto completo do artigo

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3
AM Lesokhina, B Arnulfb, R Niesvizkyc, M Mohtyd, NJ Bahlise, MH Tomassonf, P Rodrguez-Oterog, H Quachh, NS Rajei, S Iidaj, M Raabk, A Cziberel, S Sullivanl, E Leipl, A Viqueiram, V Blunkn, X Leleuo,k
a Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States
b Hôpital Saint-Louis, Paris, France
c Weill Cornell Medical College - New York Presbyterian Hospital, New York, United States
d Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
e Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
f Holden Comprehensive Cancer Center, University of Iowa, Iowa City, United States
g Clinica Universidad de Navarra, Madrid, Spain
h University of Melbourne, Melbourne
i Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States
j Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
k Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany
l Pfizer Inc, Cambridge, United States
m Pfizer SLU, Madrid, Spain
n Pfizer Inc, São Paulo, Brazil
o Centre Hospitalier Universitaire de Poitiers, Poitiers, France
Ver más
Lido
1272
Vezes
que se leu este artigo
513
Total PDF
759
Total HTML
Compartilhar estatísticas
Informação do artigo
ISSN: 25311379
Idioma original: Inglês
Dados atualizados diariamente
Ano/Mês Html Pdf Total
2025 6 20 11 31
2025 5 47 12 59
2025 4 32 13 45
2025 3 51 14 65
2025 2 43 18 61
2025 1 34 22 56
2024 12 28 10 38
2024 11 46 17 63
2024 10 37 20 57
2024 9 45 16 61
2024 8 40 18 58
2024 7 40 29 69
2024 6 33 30 63
2024 5 36 22 58
2024 4 32 22 54
2024 3 20 20 40
2024 2 22 20 42
2024 1 14 9 23
2023 12 13 22 35
2023 11 23 19 42
2023 10 16 32 48
2023 9 7 21 28
2023 8 17 18 35
2023 7 7 3 10
2023 6 10 12 22
2023 5 10 7 17
2023 4 7 5 12
2023 3 4 7 11
2023 2 6 9 15
2023 1 5 7 12
2022 12 7 15 22
2022 11 4 8 12
2022 10 3 5 8
Mostrar tudo

Siga este link para acessar o texto completo do artigo

Idiomas
Hematology, Transfusion and Cell Therapy